# T-Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.t-therapeutics.com/
- Total disclosed funding: $217M
- Latest round: Series B (Nov 5, 2026)
- Investors on record: 21

## About

Based in Cambridge, UK, and founded by Allan Bradley (CEO and Board Director) in 2022, T-Therapeutics Limited, a spin-off from the University of Cambridge, operates as a biotechnology company specializing in T cell receptors (TCR). In November 2025, T-Therapeutics Limited raised USD 24 million in series A funding co-led by new investors Tencent Investment and BGF Investment Management. Returning investors Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, and Cambridge Enterprise also participated in the round.

The company (as of November 2023) is working on the development of TCR-based drugs through its proprietary OpTiMus® platform for cancer patients. The OpTiMus® platform is a humanized TCR mouse, that generates unique, fully human TCRs not found in the human repertoire. This innovation allows T-Therapeutics to identify 'optimal' TCRs as the foundation for cancer therapies. By harnessing the natural power of T cells, these drugs aim to recognize specific cancers and mobilize the patient's own T cells to eliminate cancer cells, ultimately eradicating tumors.

The company plans to utilize the November 2025 funding to develop TCR-CD3 bispecifics for cancer and autoimmune diseases and pursue new therapies like T cell subset depletion.

## Funding rounds

- Series B, Nov 5, 2026, $133M — British Business Bank, Advent Life Sciences, Cambridge Innovation Capital, Digitalis Ventures, Eli Lilly, Eli Lilly and Company, F-Prime, JJDC, Johnson & Johnson, Johnson & Johnson Innovation, M Ventures, Samsara BioCapital, Sanofi Ventures, Sofinnova Partners, Tencent, BGF
- Series A, Nov 13, 2025, $24M — Sofinnova Partners, Cambridge Enterprise, F-Prime Capital, Tencent Investment, Sanofi Ventures, BGF Investment Management, Cambridge Innovation Capital, Digitalis Ventures
- Series A, Nov 15, 2023, $60M — Sofinnova Partners, Cambridge University Endowment Fund, F-Prime Capital, Sanofi Ventures, Cambridge Innovation Capital, Digitalis Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Cambridge University Endowment Fund — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- Cambridge Enterprise — Series A
- Tencent Investment — Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B
- Eli Lilly — Series B
- Eli Lilly and Company — Series B
- F-Prime — Series B
- JJDC — Series B
- Johnson & Johnson — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Tencent — Series B
- BGF — Series B